{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "STTK",
  "name": "Shattuck Labs, Inc.",
  "url": "https://frontierpicks.com/dossiers/STTK/",
  "json_url": "https://frontierpicks.com/dossiers/STTK.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Receptor-side TL1A: SL-325 delivered the first human data for a DR3-blocking antibody on 2026-06-08 — complete receptor occupancy at 0.1 mg/kg, anti-drug antibodies in 3.7% of dosed subjects — and the shares are up 74.1% over three months. With $208.3M cash guided to 2029 and the RECEPTIVE-CD1 Phase 2b start due inside Q3 2026, the near-term question is whether a trial-start release re-accelerates a narrative that has drifted since the 2026-08-11 print.",
  "invalidation_trigger": "A weekly close below $5.75 — the level at which the 2026-06-08 Phase 1 advance is being reversed rather than digested. Secondary: 2026-09-30 passing with no RECEPTIVE-CD1 Phase 2b initiation announced, which would break the Q3 2026 guidance given on 2026-08-11.",
  "catalyst_date": "2026-09-08",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage with no product revenue; all value rests on SL-325 in IBD until SL-846 Phase 1 data, guided to 2027.",
    "Phase 1 was conducted in 72 healthy volunteers. No patient-level efficacy data exists for SL-325 in Crohn's or ulcerative colitis.",
    "Weighted-average share count was 129.8M in Q2 2026 against a $0.24 per-share loss on a smaller absolute loss in Q2 2025 — the equity has been issued into strength.",
    "Runway guidance of 'into 2029' is management's own and explicitly excludes further capital raises or business-development proceeds."
  ],
  "body_markdown": "## Current Thesis\n\nThe narrative leg here is receptor-side TL1A. Every large-pharma bet in the TL1A/IBD space to date — Merck's April 2023 purchase of Prometheus Biosciences, Roche's October 2023 purchase of Telavant — bought a ligand-binding antibody. Shattuck's SL-325 blocks the receptor, DR3, and on 2026-06-08 it became the first DR3-blocking antibody to report human clinical data: 72 healthy volunteers, six single-ascending-dose cohorts from 0.1 mg/kg to 30.0 mg/kg, three multiple-ascending-dose cohorts from 1 mg/kg to 10 mg/kg, complete DR3 receptor occupancy at 0.1 mg/kg and above in all participants, and anti-drug antibodies detected in 3.7% of dosed participants. The shares are up 74.1% over three months, a window that contains that release.\n\nWhat an investor is buying is not efficacy — there is none yet in patients — but the claim that a validated mechanism can be hit from the receptor side with a cleaner immunogenicity profile than the ligand-side antibodies, funded to 2029, at a market value far below the class comparables. The narrative is maturing: the June dataset is now well known, both published sell-side views arrived in the second half of August (HC Wainwright to $14 on 2026-08-11, Raymond James initiating Strong Buy at $18 on 2026-08-24), and the tape has drifted rather than extended since — the 2026-09-04 close of $6.79 sits 15.8% under the 52-week high of $8.06 with RSI(14) at 39.8.\n\nNo current theme cluster carries this name, so nothing in this read leans on a group move. It is a single-name setup whose next company-dated event is a trial start, not a readout.\n\n## Bull Case\n\n- **First-in-mechanism human data, 2026-06-08.** SL-325 reported complete DR3 occupancy at doses of 0.1 mg/kg and higher in all participants, and durable inhibition of TL1A binding for months after a single dose. No other DR3 antagonist has human data.\n- **Immunogenicity is the differentiating number.** Anti-drug antibodies were detected in 3.7% of participants who received SL-325 (2026-06-08 release). Immunogenicity has been the recurring complaint against the ligand-side TL1A antibodies; this is the one biomarker where a receptor-side approach can claim a lead before efficacy exists.\n- That guidance excludes any further capital or business-development proceeds.\n- **Sell-side targets sit well above the tape.** Raymond James initiated with a Strong Buy and an $18 target on 2026-08-24; HC Wainwright maintained Buy with a $14 target on 2026-08-11. Both are multiples of the 2026-09-04 close of $6.79.\n- **A second shot on goal.** SL-846, a DR3 × IL-23 receptor bispecific, is the lead next-generation candidate with Phase 1 data expected in 2027 (2026-08-11 release).\n\n## Bear Case\n\n- **Healthy volunteers are not patients.** The 72-subject Phase 1 measured receptor occupancy, TL1A-binding inhibition and immunogenicity. It measured no Crohn's endpoint. Every TL1A-class program that has disappointed has done so in patients, not in Phase 1 pharmacology.\n- **The dead zone is long.** RECEPTIVE-CD1, the Phase 2b in Crohn's disease, was guided on 2026-08-11 to *initiate* in Q3 2026. An initiation is not a readout; on a standard Phase 2b induction timeline the efficacy answer lands well beyond 2027, and SL-846's own Phase 1 data is guided to 2027.\n- **Q2 missed and one target came down the same day.** Q2 2026 EPS was $(0.12) against a $(0.10) consensus estimate (2026-08-11), and HC Wainwright *lowered* its target to $14 on that date.\n- **Burn is scaling into the trial.** R&D was $11.7M in Q2 2026 versus $8.7M in Q2 2025; G&A was $4.5M versus $4.4M. Net loss was $15.2M versus $12.5M.\n- **The share count has done real work.** Q2 2026's $15.2M loss printed as $0.12 per share on 129.8M weighted-average shares; Q2 2025's smaller $12.5M loss printed as $0.24 per share. Inferred, not stated by the company: the denominator roughly doubled year over year, and the balance sheet moved from ~$50.5M to $208.3M in the same window. That is capital raised into strength, and it is why the runway extends to 2029.\n\n## Setup & Price Structure\n\nMeasured, from the adjusted daily series as of 2026-09-04: last close $6.79; 52-week high $8.06; 15.8% below that high; a three-month price change of +74.1%; RSI(14) at 39.8.\n\nThe shape is a post-catalyst consolidation, not a trend. The 74.1% three-month advance spans the 2026-06-08 Phase 1 release; the 15.8% give-back and a sub-40 RSI say the move has been distributing since, without a second bid appearing on either the 2026-08-11 print or the 2026-08-24 initiation. That combination — a large realised advance, coverage arriving after the move rather than before it, and momentum cooling into it — is the positioning evidence. Two named brokers now carry the story; the second one arrived at a $18 target eleven days after the first cut its own. New sell-side attention that does not lift the tape is a statement about who is already positioned.\n\nNothing in the structure supports a fresh breakout read at $6.79. The setup clears on a weekly close back above $8.06 with the Phase 2b start confirmed; it does not clear on a conference appearance.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-08** — Wells Fargo 21st Annual Healthcare Conference presentation (CEO Taylor Schreiber, CFO Andrew Neill). Fireside format; the live question is RECEPTIVE-CD1 timing and design.\n- **2026-09-09** — Cantor Global Healthcare Conference presentation. Same management, same window.\n- **~2026-09-30 (est.)** — The Q3 2026 guidance window for initiating RECEPTIVE-CD1 closes. The 2026-08-11 release put the Phase 2b Crohn's trial start inside this quarter; the calendar quarter ends 2026-09-30, which makes this the only hard company-dated test in the window.\n\n## Elapsed catalysts\n\n- **~2027 (est.)** — SL-846 (DR3 × IL-23R bispecific) Phase 1 data, per the 2026-08-11 release. Outside the window, but it defines how long the news gap runs. *(passed 26d ago)*\n\n## What Would Change Our Mind\n\nThe thesis dies quietly, not loudly. Three specific things would do it.\n\nFirst, the trial start slipping. If 2026-09-30 passes with no RECEPTIVE-CD1 initiation announcement, the Q3 2026 guidance given on 2026-08-11 has failed, and a company whose only near-term proof point is operational execution has missed it. That reframes the 2029 runway from optionality into a long, uncatalysed hold.\n\nSecond, price. A weekly close below $5.75 would say the market has stopped treating the 2026-06-08 dataset as a re-rating event and started treating it as noise — at that point the June advance is no longer being digested, it is being reversed, and the $14/$18 published targets are being ignored by the only voters who matter.\n\nThird, the mechanism. A negative patient-level readout from any ligand-side TL1A programme in Crohn's or ulcerative colitis would take the class comparable down with it, and Shattuck has no patient efficacy of its own to defend the receptor-side distinction with.\n\nConversely, a weekly close above $8.06 with the Phase 2b enrolling would confirm the base and put the narrative back into acceleration.\n\n## Correlation Notes\n\nNo published theme cluster carries STTK, so the observable correlations are inferred rather than measured here:\n\n- **TL1A-class sentiment.** Read-through runs both ways from Merck's tulisokibart and Roche's afimkibart programmes. STTK is a receptor-side derivative of a mechanism whose validation was set by pharma M&A in 2023, and class de-rating risk is not diversifiable inside this name.\n- **Small-cap clinical biotech beta.** Pre-revenue, no product sales, $208.3M cash at 2026-06-30 against a $15.2M quarterly loss. The name carries the standard rate and risk-appetite sensitivity of that cohort.\n- **Single-asset concentration.** SL-325 is the story; SL-846 is Phase 1 with data guided to 2027. There is no second programme capable of offsetting an SL-325 setback inside the next twelve months.",
  "first_seen": "2026-09-03",
  "last_analyzed": "2026-09-05T08:15:58+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}